A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen (ISIS 304801)
Sponsor: Ionis Pharmaceuticals, Inc.
A PHASE3 clinical study on Familial Chylomicronemia Syndrome, this trial is ongoing. The trial is conducted by Ionis Pharmaceuticals, Inc. and has accumulated 14 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 9 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Jul 2023 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .